A Phase 3 interventional study of Plecanatide and Placebo in Irritable Bowel Syndrome Characterized by Constipation, sponsored by Bausch Health Americas, Inc.. Completed at 191 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-06-14.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing plecanatide in Constipation — none open to participants now, 1 under way, none of them phase 3. plecanatide · Constipation.
Among the 12 studies testing plecanatide in Constipation, this one is the 4th largest by enrollment, is the only one that started in 2015, is one of 6 in phase 3, and was the 8th registered.
1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.
Browse Constipation studies →None of the 12 studies testing plecanatide in Constipation is open now. The open studies under Constipation, anywhere →
plecanatide: first FDA approval 2017 (TRULANCE). What it is approved for, and how studies give it, is on its page →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 7
First in 2010; this study’s year is marked. 1 started in 2015.
This study's enrollment of 1,135 is above the median of 75 across 885 interventional studies indexed under Constipation.
Median enrollment 800 across the 12 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 2 most frequent:
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
21 studies in Constipation by Bausch Health Companies Inc.: none open now, 1 under way, none of them phase 3. Of 20 finished, 15 (75%) have results posted.
Among the 21 studies in Constipation by Bausch Health Companies Inc., this one is the 4th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2015, is one of 8 in phase 3, and was the 17th registered.
Bausch Health Companies Inc.’s Constipation studies by the year they started, since 2006.
1 of the studies testing plecanatide in Constipation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07723924Bausch Health Americas, Inc.This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC | 2027-10-18 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing plecanatide in Constipation, from their registry updates:
Among Bausch Health Companies Inc.’s 21 in Constipation:
This tab as a report to print or save as PDF → With an account.
This study in patients with IBS-C is a randomized, double-blind, placebo-controlled, parallel-group clinical trial with 12 weeks of study drug therapy.
This study in patients with IBS-C is a randomized, double-blind, placebo-controlled, parallel-group clinical trial with 12 weeks of study drug therapy.
Screening/Baseline: Patients will undergo an up to 28-day Screening/Baseline period to allow for any necessary diagnostic procedures, allow for required washout of medications and to determine study eligibility. If otherwise eligible based on screening criteria, patients will undergo a 2-week baseline assessment using an electronic diary where they will record daily assessments of bowel movements (BMs), stool consistency (Bristol Stool Form Scale-BSFS), abdominal pain and other IBS-related symptoms. Data from the two-week electronic diary assessment just prior to the randomization visit will be used to confirm IBS-C and study eligibility as well as define the patient's baseline from which change will be determined.
Treatment: Patients who meet all entry criteria will be randomized (1:1:1) to one of three blinded treatment groups on Day 1 of the Treatment period. Patients will take an oral dose of study drug OD for 12 weeks and continue the daily electronic diaries (BMs, rescue medication use, abdominal pain, and other symptoms). During treatment weeks 4, 8, and 12, patients will return to the clinic to undergo safety and efficacy assessments.
Post-Treatment: For 2 weeks after completing dosing, patients will continue to complete daily electronic diaries. Patients will then return to the clinical site for a final follow-up visit during Week 14 following randomization.
The planned duration of participation in this study will be at least 116 days from signing of informed consent through post-treatment or up to approximately 135 days with visit windows considered.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Plecanatide 3.0 mg dosed daily for 12 weeks
Drug: Plecanatide
Plecanatide 6.0 mg dosed daily for 12 weeks
Drug: Plecanatide
Placebo dosed daily for 12 weeks
Drug: Placebo
Number of Overall Responders - ITT Population
An Overall Responder was a patient who was a weekly responder (i.e., decrease of 30% from baseline for abdominal pain intensity and an increase of at least 1 complete spontaneous bowel movement in the same week) for at least 6 of the 12 treatment weeks.
Time frame: 12 weeks
Number of Abdominal Pain Responders for at Least 6 of 12 Treatment Weeks
An Abdominal Pain Intensity Responder was a patient who had a decrease of 30 % from baseline for abdominal pain intensity. Baseline is the mean of non-missing abdominal pain scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.
Time frame: 12 Weeks
Number of Stool Frequency Responder for at Least 6 of the 12 Treatment Weeks
A Stool Frequency Responder was a patient who experienced an increase of at least one CSBM (complete spontaneous bowel movement) per week from baseline. Baseline was the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.
Time frame: 12 Weeks
Number of Sustained Efficacy Responders
A Sustained Efficacy Responder was a patient who was an Overall Responder who also was a Weekly Responder, i.e., decreased of 30% from baseline for abdominal pain intensity and increased of at least one CSBM (complete spontaneous bowel movement) in the same week for at least 2 of the 4 weeks in month 3 of the Treatment Period.
Time frame: 12 Weeks
Change From Baseline in Stool Consistency
Change from baseline in stool consistency based upon the Bristol Stool Form Scale (BSFS). Baseline was the mean BSFS score recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. BSFS Rating 1 to 7: 1. Separate hard lumps, like nuts (hard to pass) 2. Sausage-shaped but lumpy 3. Like a sausage but with cracks on its surface 4. Like a sausage or snake, smooth and soft 5. Soft blobs with clear-cut edges (passed easily) 6. Fluffy pieces with ragged edges, a mushy stool 7. Watery, no solid pieces, entirely liquid
Time frame: Baseline and 12-Week
Change From Baseline in Straining
Change from baseline in Straining Score over the 12-week treatment period. Baseline was the mean of non-missing straining scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The severity of straining during a bowel movement was measured using an 11-point scale (0-10 rating; 0 = no straining; 10 = worst straining).
Time frame: Baseline and 12-Week
Change From Baseline in CSBMs (CSBMs/Week)Complete Spontaneous Bowel Movement
Change from baseline over the 12-week Treatment Period in CSBM (Complete Spontaneous Bowel Movement) Frequency Rate (CSBMs/Week). Baseline was the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.
Time frame: Baseline and 12-Week
Number of Patients With a SBM Within 24 Hours After First Dose of Study Medication
A responder was any patient with a SBM within 24 hours after the first dose of study drug.
Time frame: Up to 24 hours after the first dose of study drug
Change From Baseline in Abdominal Pain
Change from baseline in abdominal pain as measured with an 11-point (0-10) Numerical Rating Scale from 0 (None) to 10 (Worst Possible). Baseline was the mean of the non-missing abdominal pain scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The average daily abdominal pain score was the average of the non-missing worst daily abdominal pain scores (on a 0 to 10 scale) in the given week.
Time frame: Baseline and 12-Week
| Milestone | Matching Placebo | 3.0 mg Plecanatide | 6.0 mg Plecanatide |
|---|---|---|---|
| Started | 379 | 377 | 379 |
| Completed | 329 | 328 | 325 |
| Not completed | 50 | 49 | 54 |
An Overall Responder was a patient who was a weekly responder (i.e., decrease of 30% from baseline for abdominal pain intensity and an increase of at least 1 complete spontaneous bowel movement in the same week) for at least 6 of the 12 treatment weeks.
| Participants | Matching Placebo | 3.0 mg Plecanatide | 6.0 mg Plecanatide |
|---|---|---|---|
| Number of Overall Responders - ITT Population | 54 | 81 | 91 |
An Abdominal Pain Intensity Responder was a patient who had a decrease of 30 % from baseline for abdominal pain intensity. Baseline is the mean of non-missing abdominal pain scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.
| Participants | Matching Placebo | 3.0 mg Plecanatide | 6.0 mg Plecanatide |
|---|---|---|---|
| Number of Abdominal Pain Responders for at Least 6 of 12 Treatment Weeks | 88 | 123 | 129 |
A Stool Frequency Responder was a patient who experienced an increase of at least one CSBM (complete spontaneous bowel movement) per week from baseline. Baseline was the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.
| Participants | Matching Placebo | 3.0 mg Plecanatide | 6.0 mg Plecanatide |
|---|---|---|---|
| Number of Stool Frequency Responder for at Least 6 of the 12 Treatment Weeks | 106 | 129 | 148 |
A Sustained Efficacy Responder was a patient who was an Overall Responder who also was a Weekly Responder, i.e., decreased of 30% from baseline for abdominal pain intensity and increased of at least one CSBM (complete spontaneous bowel movement) in the same week for at least 2 of the 4 weeks in month 3 of the Treatment Period.
| Participants | Matching Placebo | 3.0 mg Plecanatide | 6.0 mg Plecanatide |
|---|---|---|---|
| Number of Sustained Efficacy Responders | 53 | 78 | 90 |
Change from baseline in stool consistency based upon the Bristol Stool Form Scale (BSFS). Baseline was the mean BSFS score recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. BSFS Rating 1 to 7: 1. Separate hard lumps, like nuts (hard to pass) 2. Sausage-shaped but lumpy 3. Like a sausage but with cracks on its surface 4. Like a sausage or snake, smooth and soft 5. Soft blobs with clear-cut edges (passed easily) 6. Fluffy pieces with ragged edges, a mushy stool 7. Watery, no solid pieces, entirely liquid
| score on a scale | Matching Placebo | 3.0 mg Plecanatide | 6.0 mg Plecanatide |
|---|---|---|---|
| Baseline | 1.99 ± 1.029 | 1.91 ± 0.902 | 1.86 ± 0.912 |
| Week 12 change from baseline | 1.04 ± 1.579 | 1.55 ± 1.631 | 1.45 ± 1.621 |
Change from baseline in Straining Score over the 12-week treatment period. Baseline was the mean of non-missing straining scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The severity of straining during a bowel movement was measured using an 11-point scale (0-10 rating; 0 = no straining; 10 = worst straining).
| score on a scale | Matching Placebo | 3.0 mg Plecanatide | 6.0 mg Plecanatide |
|---|---|---|---|
| Baseline | 6.75 ± 1.848 | 6.84 ± 1.860 | 6.87 ± 1.920 |
| Week 12 change from baseline | -1.66 ± 2.149 | -2.35 ± 2.540 | -2.35 ± 2.556 |
Change from baseline over the 12-week Treatment Period in CSBM (Complete Spontaneous Bowel Movement) Frequency Rate (CSBMs/Week). Baseline was the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.
| CSBMs per week | Matching Placebo | 3.0 mg Plecanatide | 6.0 mg Plecanatide |
|---|---|---|---|
| Baseline | 0.24 ± 0.465 | 0.26 ± 0.530 | 0.27 ± 0.527 |
| Week 12 change from baseline | 0.80 ± 1.779 | 1.23 ± 2.303 | 1.63 ± 3.042 |
A responder was any patient with a SBM within 24 hours after the first dose of study drug.
| Participants | Matching Placebo | 3.0 mg Plecanatide | 6.0 mg Plecanatide |
|---|---|---|---|
| Number of Patients With a SBM Within 24 Hours After First Dose of Study Medication | 119 | 157 | 167 |
Change from baseline in abdominal pain as measured with an 11-point (0-10) Numerical Rating Scale from 0 (None) to 10 (Worst Possible). Baseline was the mean of the non-missing abdominal pain scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The average daily abdominal pain score was the average of the non-missing worst daily abdominal pain scores (on a 0 to 10 scale) in the given week.
| score on a scale | Matching Placebo | 3.0 mg Plecanatide | 6.0 mg Plecanatide |
|---|---|---|---|
| Baseline | 6.40 ± 1.624 | 6.56 ± 1.634 | 6.48 ± 1.714 |
| Week 12 change from baseline | -1.42 ± 2.116 | -2.00 ± 2.226 | -1.87 ± 2.297 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Matching Placebo | — | 1/376 (0.3%) | 13/376 (3.5%) |
| 3.0 mg Plecanatide | — | 2/375 (0.5%) | 21/375 (5.6%) |
| 6.0 mg Plecanatide | — | 3/379 (0.8%) | 22/379 (5.8%) |
| Event | Matching Placebo | 3.0 mg Plecanatide | 6.0 mg Plecanatide |
|---|---|---|---|
| Viral infectionInfections and infestations | 0/376 | 1/375 | 0/379 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/376 | 1/375 | 0/379 |
| Cartilage injuryInjury, poisoning and procedural complications | 1/376 | 0/375 | 0/379 |
| LFT abnormalInvestigations | 0/376 | 0/375 | 1/379 |
| CostochondritisMusculoskeletal and connective tissue disorders | 0/376 | 0/375 | 1/379 |
| Suicidal ideationPsychiatric disorders | 0/376 | 0/375 | 1/379 |
| Event | Matching Placebo | 3.0 mg Plecanatide | 6.0 mg Plecanatide |
|---|---|---|---|
| DiarrheaGastrointestinal disorders | 5/376 | 12/375 | 14/379 |
| HeadacheNervous system disorders | 8/376 | 9/375 | 8/379 |
| Age, Continuous(years) | Matching Placebo | 3.0 mg Plecanatide | 6.0 mg Plecanatide | Total |
|---|---|---|---|---|
| Mean | 44.8 ± 14.68 | 44.0 ± 14.61 | 43.1 ± 14.20 | 44.0 ± 14.50 |
| Sex: Female, Male(Participants) | Matching Placebo | 3.0 mg Plecanatide | 6.0 mg Plecanatide | Total |
|---|---|---|---|---|
| Female | 272 | 270 | 273 | 815 |
| Male | 107 | 107 | 106 | 320 |
Showing the first 100 of 191 sites. Choose a country and city above to see the rest.
The record gives a start of Jun 2015, a primary completion of Nov 2016 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2019, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Plecanatide
Bausch Health Americas, Inc. →